Intellipharmaceutics’ Oxycodone ER Returns To US FDA Panel Looking For Abuse-Deterrence Claim

15 Jan 2020

Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.

Addict man make injection of drugs — Aximris XR can be expected to have some deterrent effect by the intravenous route of abuse, the FDA says. • Source: Shutterstock

Intellipharmaceutics’ Oxycodone ER Returns To US FDA Panel Looking For Abuse-Deterrence Claim

More from US FDA Performance Tracker

More from Regulatory Trackers